1	MARY ANN SMITH
2	Deputy Commissioner MIRANDA LEKANDER
3	Assistant Chief Counsel LINDSAY HERRICK (State Bar No. 224986)
4	Counsel Department of Business Oversight
5	1515 K Street, Suite 200 Sacramento, California 95814
6	Telephone: (916) 445-3682 Facsimile: (916) 445-8730
7	Attorneys for Complainant
8	
9	BEFORE THE DEPARTMENT OF BUSINESS OVERSIGHT
10	OF THE STATE OF CALIFORNIA
11	In the Matter of:
12	THE COMMISSIONER OF BUSINESS) SETTLEMENT AGREEMENT OVERSIGHT,)
13	Complainant,
14	v.
15	MED-X, INC., DAVID E. TOOMEY, () MATTHEW A. MILLS and RONALD J. ()
16	TCHORZEWSKI,
17	Respondents.
18	
19	This Settlement Agreement is entered between the Department of Business Oversight
20	(Department) through the Commissioner of Business Oversight (Commissioner), on the one hand,
21	and Med-X, Inc., David E. Toomey, Matthew A. Mills and Ronald J. Tchorzewski (collectively,
22	Respondents) on the other hand (hereafter, the Parties), and is made with respect to the following:
23	RECITALS
24	A. At all relevant times, Med-X, Inc. (Med-X) was a Nevada corporation doing business
25	at 8236 Remmet Avenue, Canoga Park, California 91304.
26	B. At all relevant times, Dr. David E. Toomey (Toomey) was Director and Chief
27	Executive Officer of Med-X.
28	C. At all relevant times, Matthew A. Mills (Matthew Mills) was Chairman of the Board,
	-1-
	SETTLEMENT AGREEMENT

1 President and Chief Operating Officer of Med-X.

D. At all relevant times, Ronald J. Tchorzewski (Tchorzewski) was Director and Chief
Financial Officer of Med-X.

E. Beginning in or about September 1, 2014, Toomey, Matthew Mills, Tchorzewski and Med-X offered or sold securities in the form of common stock of Med-X. Toomey, Matthew Mills, Tchorzewski and Med-X conducted a series of offerings in Med-X, including but not limited to the following:

 Beginning in or about September 1, 2015, Toomey, Matthew Mills, Tchorzewski and Med-X offered or sold shares of common stock with a 30,000-share minimum investment requirement at 50 cents per share to raise \$2.5 million.

Beginning in or about February 3, 2016, Toomey, Matthew Mills, Tchorzewski and
 Med-X offered or sold shares of common stock with a 700-share minimum investment requirement at
 60 cents per share to raise \$15 million.

iii. Beginning in or about October 1, 2016, Toomey, Matthew Mills, Tchorzewski and Med-X offered or sold shares of common stock in two separate offerings each with a 20,000-share minimum investment requirement at 60 cents per share to raise \$1.2 million for each offering.

F. The purported purpose of the offerings was to raise funds to engage in activities related to the cannabis industry, including but not limited to acquiring, creating and publishing Cannabis-related media content through Med-X's website (www.marijuanatimes.org), distributing or selling Nature-Cide® products to cannabis cultivators, and researching and developing cannabis to market and/or sell for medical and/or recreational purposes. Investors were told that Nature-Cide® is owned, manufactured and distributed by Pacific Shore Holdings, Inc., an affiliate and principal shareholder of Med-X which has granted to Med-X an exclusive license to use and market the brand. The Commissioner previously issued a Desist and Refrain Order to Pacific Shore Holdings, Inc. on August 7, 2013 for offering and/or selling non-exempt securities without a permit in violation of Corporations Code section 25110 in an offering involving raising funds for Nature-Cide®.

G. According to the February 3, 2016 Offering Circular, beginning on April 1, 2015,
Med-X employed Arthur Avanesov (Avanesov) as one of its "Significant Employees" in the position

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

1 of Investor Relations.

2 H. Avanesov was not disclosed by Med-X in its earlier Private Placement Memorandum 3 provided to investors for the September 1, 2015 offering, nor in its Private Placement Memorandums for the two later offerings, each dated October 1, 2016, even though Avanesov continued to hold the 4 5 position of Investor Relations/Business Development with Med-X.

I. In connection with these offers and sales, Toomey, Matthew Mills, Tchorzewski and Med-X also omitted to disclose to investors that Avanesov had been issued a Desist and Refrain Order (Order) by the Commissioner on July 27, 2010 for violations of Corporations Code sections 25110, 25401, 29535 and 29536. The Order became final on January 14, 2011 after Avanesov requested and appeared at the hearing to challenge the Order.

K. Med-X investors were not told that the Commissioner found that Avanesov had offered foreign exchange trading accounts while acting as a trading advisor for trading currencies on the foreign exchange market without being registered, licensed or exempt in violation of Corporations Code section 29535. The Commissioner also found that Avanesov had offered or sold unqualified securities in violation of Corporations Code section 25110 in the form of equity positions in Welland Capital, Inc. which Avanesov oversaw as its President. The Commissioner also found that Avanesov had offered or sold commodities and securities by means of communication that included an untrue statement of material fact or omitted to state a material fact necessary in order to make the statement not misleading in violation of Corporations Code sections 25401 and 29536.

20 L. The Commissioner is of the opinion that the shares of common stock offered or sold in Med-X, Inc. are securities under the Corporate Securities Law of 1968 (CSL) (Corp. Code, § 25000 22 et seq.) and were offered or sold in this state by means of written or oral communications which 23 included an untrue statement of a material fact or omitted to state a material fact necessary in order to 24 make the statements made, in light of the circumstances under which they were made, not 25 misleading, in violation of Corporations Code section 25401.

26 M. Respondents admit to the jurisdiction of the Commissioner with respect to the subject 27 matter hereof and agree to the execution of this Settlement Agreement as a resolution of the matter 28 without the need to initiate litigation.

6

7

8

9

10

11

12

13

14

15

16

17

18

19

21

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

1N.The Commissioner finds this Settlement Agreement is appropriate, in the public2interest, and consistent with the purposes fairly intended by the policy and provisions of the CSL.

NOW THEREFORE, in consideration of the foregoing, and the terms and conditions set forth herein, the Parties agree as follows:

TERMS AND CONDITIONS

1. <u>Purpose</u>. The purpose of this Settlement Agreement is to resolve the foregoing issues in a manner that avoids the expense of a hearing and possible other court proceedings. Respondents stipulate to the terms of this Settlement Agreement without admitting or denying any of the findings of the Commissioner regarding the subject matter of this Settlement Agreement. The Parties hereby acknowledge and agree that this Agreement is intended to constitute a full, final and complete resolution of this matter.

2. <u>Agreement to Desist and Refrain</u>. Respondents agree to desist and refrain from offering or selling or buying or offering to buy any security in the State of California, including but not limited to shares of common stock, by means of any written or oral communication which includes an untrue statement of a material fact or omits to state a material fact necessary in order to make the statements made, in light of the circumstances under which they are made, not misleading in violation of Corporations Code section 25401.

18 3. Future Actions by the Commissioner. The Parties acknowledge and agree that 19 nothing contained in this Settlement Agreement shall operate to limit the Commissioner's ability to 20 assist any other agency, (county, state or federal) with any prosecution, administrative, civil or 21 criminal, brought by any such agency against Respondents based upon the subject matter hereof or 22 otherwise. This Settlement Agreement shall not limit the ability of the Commissioner to bring any 23 administrative or civil action to enforce compliance with this Settlement Agreement or to seek 24 penalties for its violation. Further, the Commissioner reserves the right to bring any future action(s) 25 against Respondents or any of the managers, officers, directors, shareholders or employees of 26 Respondents for all unknown or future violations of the CSL.

4. <u>Independent Legal Advice</u>. Respondents represent, warrant, and agree that they have
had the opportunity to seek independent advice from legal counsel and/or representative with respect

1 || to the advisability of executing this Settlement Agreement.

2 5. No Other Representation. Each of the Parties represents, warrants, and agrees that in 3 executing this Settlement Agreement each has relied solely on the statements set forth herein and the 4 advice of its own counsel and/or representative. Each of the Parties further represents, warrants, and 5 agrees that in executing this Settlement Agreement it has placed no reliance on any statement, 6 representation, or promise of any other party, or any other person or entity not expressly set forth 7 herein, or upon the failure of any party or any other person or entity to make any statement, 8 representation or disclosure of anything whatsoever. The Parties have included this clause: (1) to 9 preclude any claim that any party was in any way fraudulently induced to execute this Settlement 10 Agreement; and (2) to preclude the introduction of parol evidence to vary, interpret, supplement, or 11 contradict the terms of this Settlement Agreement.

6. <u>Modifications and Qualified Integration</u>. No amendment, change or modification to this Settlement Agreement shall be valid or binding to any extent unless it is in writing and signed by all the parties affected by it.

7. <u>Full Integration</u>. This Settlement Agreement is the final written expression and the complete and exclusive statement of all the agreements, conditions, promises, representations, and covenants between the parties with respect to the subject matter hereof, and supersedes all prior or contemporaneous agreements, negotiations, representations, understandings, and discussions between and among the parties, their respective representatives, and any other person or entity, with respect to the subject matter covered hereby.

8. <u>No Presumption from Drafting</u>. In that the Parties have had the opportunity to draft,
review and edit the language of this Settlement Agreement, no presumption for or against any party
arising out of drafting all or any part of this Settlement Agreement will be applied in any action
relating to, connected, to, or involving this Settlement Agreement. Accordingly, the Parties waive the
benefit of Civil Code section 1654 and any successor or amended statute, providing that in cases of
uncertainty, language of a contract should be interpreted most strongly against the party who caused
the uncertainty to exist.

28

9.

Effect Upon Future Proceedings. If Respondents apply for any license, permit or

12

13

14

15

16

17

18

19

20

qualification under the Commissioner's current or future jurisdiction, or are the subject of any future
 action by the Commissioner to enforce this Settlement Agreement, then the subject matter hereof
 shall be admitted for the purpose of such application(s) or enforcement proceedings(s).

10. <u>Counterparts</u>. This Settlement Agreement may be executed in one or more counterparts, each of which shall be an original but all of which, together, shall be deemed to constitute a single document.

11. <u>Terms, Headings and Governing Law</u>. All terms used, but not defined herein, shall have the meaning assigned to them by the CSL. The headings to the paragraphs of this Settlement Agreement are inserted for convenience only and will not be deemed a part hereof or affect the construction or interpretation of the provisions hereof. This Settlement Agreement shall be construed and enforced in accordance with, and governed by, the laws of the State of California.

12. <u>Authority for Settlement</u>. Each party warrants and represents that such party is fully entitled and duly authorized to enter and deliver this Settlement Agreement. In particular, and without limiting the generality of the foregoing, each party warrants and represents that it is fully entitled to enter the covenants, and undertake the obligations set forth herein.

13. <u>Public Record</u>. Respondents acknowledge that this Settlement Agreement is a public record. Respondents further understand and agree to not make any statement or representation that is inconsistent with the Settlement Agreement.

14. <u>Voluntary Agreement</u>. The Parties each represent and acknowledge that in executing this Settlement Agreement, each does so completely voluntarily and without any duress or undue influence of any kind from any source.

15. <u>Effective Date</u>: This Settlement Agreement shall become effective when executed by
the Commissioner or her designee and transmitted by electronic mail (email) to Respondents at
lesterwinograde@verizon.net.

JAN LYNN OWEN Commissioner of Business Oversight

By: \overline{MA}

MARY ANN SMITH Deputy Commissioner Enforcement Division

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21


25

26

27

28

Dated: 9/6/17



State of California - Department of Business Oversight